There has been an alarming increase in opioid addiction in the last twenty years in the US. The number of people who died from an opioid-related overdose has quadrupled since 1999.Reference Volkow and McLellan1 Two important drivers of the opioid epidemic have been the under-treatment of opioid use disorders and the aggressive marketing strategies of pharmaceutical companies.Reference Sarpatwari, Sinha and Kesselheim2 One potential source of novel policy approaches to address these two contributing factors can be found among the countries of Western Europe, where fewer people die of opioid abuse and where prescription rates for opioids are currently 2.5 to 4 times lower than in the US.Reference van Amsterdam and van den Brink3
Educational Work and Information Campaigns
There is substantial unmet demand for opioid abuse treatment among the general population in the US. For example, fewer than 22% of patients suffering from opioid use disorder received treatment between 2009 and 2013.4 This gap has been traced to a shortage of treatment centers, a lack of physician training, and the unfortunate preconception by some that opioid use disorder is a moral weakness or a willful choice.Reference Sarpatwari, Sinha and Kesselheim5
By contrast, it has been estimated that between 71% and 88% of all patients with opioid use disorder are being treated in Switzerland.6 Equivalent results are also true for other Western European countries, such as Germany.7 According to Switzerland's Federal Office for Public Health, which recognized the danger of opioid abuse in the last century and focused on both, prevention and treatment, addressing opioid use disorder includes (1) education of patients, physicians, as well as society and (2) development of guidelines for the coordinated treatment of patients suffering from opioid use disorder. The educational work involves especially understanding of opioid use disorder as a chronic medical illness and the heterogeneity of the patient population. Opioid use disorder can occur as a primary condition or as a secondary disease due to another underlying illness and can affect all levels of society. The goal of this educational work is to make physicians and patients suffering from opioid use disorder aware of possible treatment options and to reduce stigmatization by avoiding the misconception of opioid abuse as a moral weakness or a willful choice.8
The guidelines that have been disseminated aim to lower the threshold for accessing the treatment of opioid use disorder, enhance the accessibility to treatment in a wide range of environments (e.g., hospitals, medical practices, pharmacies, and prisons) reach as many patients as possible, and coordinate patients' medical services. The guidelines address especially primary care physicians since it is estimated that 60% of the patient population is being treated by this group of physicians. The guidelines include details on how to treat patients suffering from opioid use disorder, but also emphasize the importance of coordinating with specialists (such as psychiatrists or pain specialists), non-physician experts (e.g., psychologists or social workers) and the government to achieve long-term treatment.9
In the US, while the government and medical professional associations are already focusing on the development of guidelines with regard to the prevention and treatment of opioid use disorder, they should likewise additionally support educational efforts to reduce current misconceptions of opioid abuse and instead support its re-framing as a chronic disease to achieve an open dialogue that would potentially result in a better understanding and earlier treatment.
Regulating the Marketing of Pharmaceutical Companies
In the US, pharmaceutical manufacturers engage in aggressive marketing of their products.Reference Sinha, Kesselheim and Darrow10 These efforts helped promote overuse of opioids during the early stages of the current opioid epidemic. In one notable example, more than five thousand clinicians attended forty all-expenses-paid pain conferences in which Purdue Pharma promoted extended-release oxycodone (OxyContin). Due to these and other marketing activities, annual sales of extended-release oxycodone grew to exceed $2 billion between 1996 and 2014.11
In response to the US opioid epidemic, it can be helpful to look beyond national borders to evaluate novel approaches. A stronger focus on education to reduce stigmatization and an intensified engagement of the medical associations with regard to the regulation of pharmaceutical marketing represent potential solutions.
The marketing of drugs is more strongly regulated in Western European countries, where it is generally prohibited to grant, offer, or promise benefits to physicians who prescribe drugs or to the organizations that employ them.12 The prohibition does not only include monetary benefits or material presents, but would also cover all-expenses-paid conferences by the pharmaceutical company at lavish resorts. This prohibition is not only rigorously enforced by governments, but medical associations also implemented this prohibition in their codes of conduct and strictly enforce this prohibition against their member physicians. For example, in 2013 the medical associations in Germany penalized 163 physicians who accepted benefits from the pharmaceutical company Ratiopharm and who in return favored those products for the treatment of their patients.13 As a result, less heavy marketing of prescription drugs overall is conducted in Western Europe compared to the US.
In recent years, some academic institutions in the US have taken steps to stem direct pharmaceutical manufacturer promotion to physicians (state governments have been stymied by the expanding reach of courts' interpretations of First Amendment protections for commercial speech). In addition, guidelines and codes of conduct disseminated by medical associations can have a significant influence on the behavior of physicians and their interactions with pharmaceutical manufacturers. Medical associations in the US could look to the strategies employed by their European counterparts to help address aggressive marketing of opioids by pharmaceutical manufacturers.
Conclusion
In response to the US opioid epidemic, it can be helpful to look beyond national borders to evaluate novel approaches. A stronger focus on education to reduce stigmatization and an intensified engagement of the medical associations with regard to the regulation of pharmaceutical marketing represent potential solutions.
Acknowledgements
The author would like to thank Aaron S. Kesselheim, M.D., M.P.H., J.D. for his comments on a prior draft.
